Company intelligence / Profile preview

Others

Conshohocken, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Othera Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for ophthalmic diseases. The company's lead candidate, OT-551, was an eye drop formulation designed to treat dry age-related macular degeneration (AMD) by targeting oxidative stress and inflammation. Despite reaching Phase 2 clinical trials, the company faced challenges in demonstrating sufficient efficacy, leading to a cessation of operations. Othera's research primarily targeted the prevention of vision loss associated with retinal degeneration and other ocular conditions.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Others.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Others.

Explore the full profile